Pindolol: A New β-Adrenoceptor Antagonist with Partial Agonist Activity

Publisher Website
Google Scholar
Abstract
Pindolol (Visken) is a β-adrenoceptor antagonist that was released in November 1982 for clinical use in the United States (Fig. 1). After propranolol, metoprolol, nadolol, atenolol, and timolol, it is the sixth orally active β-blocker to be approved by the Food and Drug Administration for the treatment of systemic hypertension. The drug has been marketed widely outside the United States since 1969 for hypertension, angina pectoris, and arrhythmias.Despite the therapeutic similarity of the β-blocking drugs, some differences in their pharmacodynamic and pharmacokinetic properties may be clinically important.1 The β-blockers are usually classified according to the presence or absence of . . .